Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Assets (2016 - 2026)

Intellia Therapeutics has reported Current Assets over the past 12 years, most recently at $466.4 million for Q1 2026.

  • Quarterly Current Assets fell 15.41% to $466.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $466.4 million through Mar 2026, down 15.41% year-over-year, with the annual reading at $527.7 million for FY2025, 17.53% down from the prior year.
  • Current Assets was $466.4 million for Q1 2026 at Intellia Therapeutics, down from $527.7 million in the prior quarter.
  • Over five years, Current Assets peaked at $1.2 billion in Q4 2022 and troughed at $466.4 million in Q1 2026.
  • The 5-year median for Current Assets is $858.9 million (2022), against an average of $779.8 million.
  • Year-over-year, Current Assets skyrocketed 62.98% in 2022 and then plummeted 37.63% in 2025.
  • A 5-year view of Current Assets shows it stood at $1.2 billion in 2022, then fell by 17.95% to $998.3 million in 2023, then plummeted by 35.91% to $639.9 million in 2024, then dropped by 17.53% to $527.7 million in 2025, then fell by 11.61% to $466.4 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Current Assets are $466.4 million (Q1 2026), $527.7 million (Q4 2025), and $581.9 million (Q3 2025).